Dose the first patient in the RP2 biliary tract cancer cohort
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 7 Aug 2025
- Due
- 31 Dec 2025
- Delivered
- Q4 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“the Company expects to dose its first patient in the second half of 2025 in a cohort evaluating RP2 in patients with biliary tract cancer.”
What we found
Evidence strength A What the grades mean
The company confirmed that it enrolled and dosed the first patients in the RP2 biliary tract cancer cohort during the fourth quarter of 2025, meeting the second-half 2025 deadline.
-
A Replimune Group, Inc. 8-K filed 2026-01-12
“First patients enrolled in BTC cohort in Q4 2025” ✓ confirmed on the page
-
A Replimune Group, Inc. 10-Q filed 2026-02-03
“We have also opened a cohort in our RP2 study to enroll patients with biliary tract cancer, or BTC, and dose RP2 in combination with durvalumab. This cohort enrolled the first patients in the fourth quarter of 2025.” ✓ confirmed on the page
Market reaction: the shares moved -3.5% against the S&P 500 over the three sessions around the disclosure (9 Jan 2026 to 14 Jan 2026). What this measures
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Dose
- Deliverable
- First patient dose in RP2 biliary tract cancer cohort
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Replimune Group, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-REPL-002750 · Corrections policy